Fluorescent Immunoassay Market Scope And Analysis

  • Report Code : TIPRE00011093
  • Category : Biotechnology
  • No. of Pages : 150
Buy Now

Fluorescent Immunoassay Market Scope and Analysis Report by 2028

Buy Now


Fluorescent Immunoassay Market Report Scope

Report Attribute Details
Market size in 2023 US$ 2.81 Billion
Market Size by 2031 US$ 4.51 Billion
Global CAGR (2023 - 2031) 5.8%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Product Type
  • ELISA
  • Rapid Lateral Flow Immunoassay
By Application
  • Infectious Diseases
  • Oncology
  • Cardiovascular Diseases
By End User
  • Hospitals and Clinics
  • Diagnostic Centers
  • Pharmaceutical & Biotechnology Companies
  • Academic and Research Institutes
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Abbott
  • BD
  • bioMerieux SA
  • F Hoffman La Roche Ltd
  • Siemens AG
  • Sysmex Corp
  • Thermo Fisher Scientific Inc
  • Quidel Corp
  • Ortho Clinical Diagnostics Holdings plc
  • Danaher
  • Fluorescent Immunoassay Market News and Recent Developments

    The fluorescent immunoassay market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the fluorescent immunoassay market are listed below:

    • Roche announced that it has launched a high-throughput SARS-CoV-2 antigen test as an aid in the diagnosis of SARS-CoV-2 infections. The laboratory-based Elecsys SARS-CoV-2 Antigen test had earlier received CE mark and has recently obtained the import license from CDSCO (Source: F. Hoffmann-La Roche Ltd., Press Release, June 2021)
    • Ortho Clinical Diagnostics announced its quantitative COVID-19 IgG antibody test achieved CE Mark. Ortho’s VITROS Anti-SARS-CoV-2 IgG Quantitative Antibody test is traceable to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which is developed to facilitate the standardization SARS-CoV-2 serological methods. (Source: Ortho Clinical Diagnostics, Newsletter, May 2021)
    • Ortho Clinical Diagnostics announced the US FDA granted Emergency Use Authorization to its second COVID-19 antibody test—the VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Test (COVID-19 IgG antibody test). (Source: Ortho Clinical Diagnostics, Newsletter, April 2021)

    Fluorescent Immunoassay Market Report Coverage and Deliverables

    The “Fluorescent Immunoassay Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Fluorescent immunoassay market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Fluorescent immunoassay market trends as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Fluorescent immunoassay market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the fluorescent immunoassay market
    • Detailed company profiles